ISRCTN10521680Active, not recruitingPhase 1
Phase I trial, Quotient code: QSC205601 [The full scientific title will be published within 30 months after the end of the trial]
ovartis (Switzerland)0 sites116 target enrollmentStarted: February 1, 2022Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 1
- Status
- Active, not recruiting
- Sponsor
- Enrollment
- 116
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Other
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Healthy human volunteer
Exclusion Criteria
- •The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record when the results are published, which will be within 30 months after the trial has ended.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Phase I trial Quotient code: QSC206365The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.Not SpecifiedISRCTN27020581Relay Therapeutics (United States)6
Completed
Phase 1
Phase I trial Quotient Code: QSC207682The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.Not SpecifiedISRCTN10750305Constellation Pharmaceuticals (United States)8
Active, not recruiting
Phase 1
Phase I trial Quotient Code: QSC206680Healthy volunteersISRCTN12656966Emplicure AB12
Active, not recruiting
Phase 1
Phase I trial: Quotient Code QSC207871The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.ISRCTN12178605ovartis Pharma AG43
Active, not recruiting
Phase 1
Phase I trial, Quotient Code: QSC208063The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.ISRCTN17473850Trevena, Inc.72